respectively. In our study, we found that MPV had higher sensitivity and specificity in contrast to platelet count. MPV may used as predictor for early detection of ACS and risk stratification when other cardiac biomarkers are negative.
Introduction
Acute coronary syndrome (ACS) is a set of signs and symptoms due to rupture of a plaque and are a consequence of platelet rich coronary thrombus formation. 1 Platelets have a major role in the pathogenesis of acute coronary syndrome (ACS), where plaque rupture is followed by platelet activation and thrombus formation. 2 Platelet activation is the key step of pathogenesis of acute coronary syndrome. 3 Activated platelets are larger in size, which can be measured by mean platelet volume (MPV). Larger platelets are more adhesive and tend to aggregate more as they more dense granules. They are metabolically and enzymatically more active than small platelets and produce more thromboxane A2. 4, 5, 6 Increased platelet volume will increase the tendency for coronary thrombus formation in ACS patients. 7 The activated platelet is the major biological risk factor for pathogenesis of ACS, soinhibition of this process could play an important role in prevention of ACS. 8 That's why anti-platelet therapy like aspirin and clopidogrel are used to prevent platelet activity.
The diagnostic criteria of ACS are clinical presentation, biochemical markers of acute ischemic injury, and electrocardiographic findings. 9,10 The present cardiac markers are not sufficiently sensitive at an early stage of ACS. That's why an early and reliable marker is needed for accurate diagnosis of ACS when patients will attend in cardiac emergency department. Platelet parameters especially MPV could be an important and reliable markers in early detection of ACS when other markers are not available. This could lower the morbidity and mortality rates.
Methods
This interventional quasi-experimental study was conducted in Department of Clinical Pathology, in collaboration with Department of Cardiology, BSMMU and BIRDEM from September 2011 to August 2012. Total 142 adult (18 years above) patients with clinically suspected acute coronary syndrome who attended in cardiac emergency and admitted in coronary care unit (CCU) in the department of Cardiology, BSMMU, and BIRDEM, Dhaka were enrolled in this study. Among them 79 patients had ECG changes (ST-elevation, ST-depression, T-inversion, appearance of Q-wave) with or without elevated troponin I and treated with anti-platelet drugs. They were considered as cases(group I). The rest 63 patients had normal ECG findings, normal cardiac troponin I and did not receive anti-platelet therapy. They were comsidered as as controls (group II). Clinical history, medical reports, findings and information were documented in a pre-designed data sheet with informed and written consent. Blood was collected aseptically for CBC and MPV with EDTA tube and determined by automated Haematology analyzer (Sysmex XT-4000i) on 1st day when patient admitted in emergency unit and ongoing 5th day in CCU.
Data were processed and analyzed by using computer software SPSS (Statistical package for social sciences version 16) by applying appropriate formula. Data were analysed by mean with standard deviation (SD), t-test, and Chi-square test with 95% confidence interval. Test of validity was calculated by receiver operative characteristic analysis curves.
In present study males were predominant in both groups, 57(72.2%) in group I, and 44 (69.8%) in group II. (Figure-1 ) In 1st sample, the mean (±SD) platelet count on admission before anti-platelet therapy was 273.1(±50.15) 109/L and 290.78(±74.86) 109/L in group I and group II respectively. Difference between two groups was not statistically significant (P=0.096). In 2nd sample, on 5th day of treatment, the mean (±SD) platelet count was 284.56(±41.93) 109/L in group I. In-group I, the mean platelet count difference in 1st& 2nd samples was not statistically significant (P=0.052). Receiver-operator characteristic (ROC) curves were constructed using MPV value of the patients between two groups, which gave cut off value of >10.7 fl as the value with a best combination of sensitivity and specificity for acute coronary syndrome. MPV had the best area under curve compared to platelet counts.Platelet count cut-off value was>225X109/L showed sensitivity 83.0% and specificity 28.1% in the diagnosis of acute coronary syndrome where MPV showed sensitivity 90.6% and specificity 49.4% in the diagnosis of acute coronary syndrome.
Bangladesh Med J. 2013 May; 42 (2) s= significant, ns= not significant, P a = value reached from unpaired t-test, P b = value reached from paired t-test R Paudel et al, 20 P Joshi. 21 This may be due to prevalence of current and former smoking, and higher alcohol consumption in male than female in Bangladesh.
In our study, we found that ACS was associated with abnormal platelet parameters. The study reveals that the mean (±SD) value of total platelet count was lower in cases than controls where as MPVwas significantly higher in group I than group II. In our study, total platelet count was 273. Mean platelet parameters before and after anti-platelet therapy of the study patients (n=142).
1-Specificity Sensitivity
In present study, sensitivity and specificity of MPV were 90.6% and 49.4% respectively. Hsin Chu et al 1 and AS Yasar et al 33 observed in their studies that MPV was significantly higher in patients with acute myocardial infarction and unstable angina in comparison to control subjects. They found that in patients with ACS, the best cut off value of MPV was 10.35 fl and 8.88 fl. Sensitivity and specificity were 78.3% & 70.4% and 74.6% & 66.1% respectively. In our study, the sensitivity and specificity of platelets counts were 83% and 28.1% respectively. The positive and negative predictive values were 37.6% and 64%.
The sensitivity, specificity, positive and negative predictive values were determined through ROC curves against troponin I. In our study among the 79 cases, 53 were troponin I positive and 26 were negative. All of the control subjects were troponin I negative. According to diagnostic criteria 67 cases were diagnosed as AMI and 12 cases were UA where troponin I was negative. Among 67 AMI cases, only 53 cases were troponin I positive in 1st sample and 14 cases were initially troponin I negative and became positive later. That is why specificity was low in our study in compared to study done by Hsin Chu et al 1 and AS Yasar et al. 33 Because there was similar result of platelet parameters found in troponin I positive and negative subjects in group I.
In present study, total counts of platelet in group I before and after anti-platelet therapy were 273.1±50.15x109/L and 284.56±41.93x109/L respectively. This denotes no significant differences between the samples. Considering MPV, we found significant differences before and after anti-platelet therapy, but not below the cut off values. There are two hypotheses that described the increased platelet volume. First, when platelets are activated they change their size and shape (metamorphosis). Second, after platelet activation aggregation of more platelet this leads to release of younger platelet from bone marrow. These suggest that MPV is indirect indicators of platelet activation and its association with ACS. After anti-platelet therapy, MPV was decreased, due to inhibition of platelet activation and aggregation.
These findings lead to the hypothesis that larger platelets as determined by their volumes (MPV) may be useful markers in patients with ACS. Our data indicate that, higher MPV may become useful marker for early detection of ACS along with other biomarkers. Larger platelets are haemostatically more active and carry risk for developing coronary thrombosis leading to ACS. Patients with increased MPV could be easily identified during routine haematological analysis. It could play an important role in early detection of acute coronary syndrome (ACS) and beneficial for preventive treatment. It could be used as a screening test to differentiate the origin of chest pain along with other cardiac biomarkers.
count was slightly lower in ACS group than control subjects. MPV were significantly higher in ACS groups in compared to control groups. They described platelets parameters mainly MPV was raised in ACS compared to controls.
A study done by S Nandwani et al 23 in India found that platelet volume indices were raised in patients with ACS compared with controls. MPV was 10.78 µm 3 in acute myocardial infarction and 11.73 µm3 in unstable angina. Another study done in India conducted by MM Khandekar et al 24 suggested that all platelet volume indices were increased significantly in patients with acute myocardial infarction and unstable angina compared to subjects of stable coronary artery disease. The authors found platelet volume indices especially, MPVwas 10.43±1.03 fl. Our findings are consistent with these studies. The findings of platelet count and MPV also consistent with a number of studies, done by E Varol et al, 25 R Cemin et al 26 and Yilmaz et al. 27 They found that MPV was significantly higher in patients with ACS groups than controls, along with reverse changes in platelet count. E Varol et al 25 found, platelet count 291±16.2 X 109/L and MPV 9.9±1.8 fl. Yilmaz et al 27 shown, 248±48 x 109/Land MPV were 10.7±0.7 fl in UA groups and 10.4±0.6 fl in MI groups. L Pizzuli et al, 28 R Mercan et al 4 and MP Ranjith et al 29 found platelet counts were significantly lower in the ACS groups as compared to control subjects, but MPV was significantly higher in ACS. R Sewell et al 30 described in their study that high MPV after MI was associated with consumption of small platelet and release of young platelet from bone marrow. Our study is consistent with study done by other authors.
Platelets are heterogeneous cells with size, density and activity. 31 Platelet volume is an important indicator for platelet function and activation. There are many studies reported where platelet volume had association with ACS. Independent association of MPV in AMI was shown by G Endler et al. 2 They also showed that higher the MPV (>11.6 fl) higher the risk of MI. Park et al 32 considered increased MPV to be a risk factor for platelet activation. Z Huczek et al, 7 AS Yasar et al, 33 Y Kucukardali et al 34 and A Kenneth et al 35 observed in their studies that increased MPV (>9.8±1.5 fl, >10.3fl and >10.7 fl) on admission predicts impaired reperfusion, where there is activation of platelet before AMI begins, and consequently, there are more death occur in those patients after thrombolytic therapy. The MPV remain increased upto 5/6 days suggest that the activity of platelets remain constant. SG Chu et al 36 found that MPV was associated with patients AMI by a systemic review and Meta analysis. They observed increased MPV (>9.42 fl) in AMI were 14 studies among 16 studies. They described MPV as a risk factor and prognostic indicator in cardiovascular disease. Similar fingings were obtained by RE Ulusoy et al 37 in STEMI, where the platelet count was low.
